Table 3.
Univariate and Multivariate Survival Analyses in Combined Validation Cohorts
| Characteristic | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| N stage | ||||||
| N0 | Ref | Ref | ||||
| N1 | 3.19 | 2.53 to 4.02 | < .01 | 1.81 | 1.38 to 2.39 | < .01 |
| T stage | ||||||
| T1 | Ref | Ref | ||||
| T2 | 1.45 | 0.99 to 2.11 | .06 | 1.02 | 0.68 to 1.55 | .92 |
| T3 | 3.60 | 2.77 to 4.68 | < .01 | 1.93 | 1.39 to 2.68 | < .01 |
| T4 | 9.04 | 4.31 to 18.94 | < .01 | 6.93 | 2.94 to 16.36 | < .01 |
| Age (per year increase) | 1.01 | 1.00 to 1.02 | .03 | 1.02 | 1.01 to 1.03 | < .01 |
| Sex | ||||||
| Female | Ref | Ref | ||||
| Male | 1.15 | 0.87 to 1.52 | .31 | 1.03 | 0.77 to 1.37 | .85 |
| Radicality | ||||||
| R0 | Ref | Ref | ||||
| R1 | 2.75 | 2.19 to 3.46 | < .01 | 1.65 | 1.26 to 2.15 | < .01 |
| Histology grade (differentiation) | ||||||
| Well | Ref | Ref | ||||
| Moderate | 3.01 | 1.59 to 5.71 | < .01 | 1.74 | 0.90 to 3.36 | .10 |
| Poor | 5.67 | 3.01 to 10.68 | < .01 | 2.81 | 1.45 to 5.43 | < .01 |
| Chemotherapy | ||||||
| No | Ref | Ref | ||||
| Yes | 0.64 | 0.43 to 0.94 | .02 | 0.63 | 0.41 to 0.96 | .03 |
| Study center | ||||||
| Pittsburgh | Ref | Ref | ||||
| Rotterdam | 1.22 | 1.00 to 1.48 | .05 | 0.94 | 0.75 to 1.19 | .62 |
| IHC panel (per score increase) | 1.30 | 1.12 to 1.50 | < .01 | 1.20 | 1.03 to 1.40 | .02 |
Abbreviations: HR, hazard ratio; IHC, immunohistochemistry; Ref, reference.